0
Upcoming Allied Market Research
2023
Pharmerging Market

Pharmerging Market

by Product Type (Pharmaceuticals, Healthcare), by Economy (Tier-1, Tier-2, Tier-3), by Indications (Lifestyle Diseases, Cancer and autoimmune diseases, Infectious Diseases, Others) and by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, E-commerce, Drug stores): Global Opportunity Analysis and Industry Forecast, 2023-2032

Report Code: A02479
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pharmerging Market

Request Now !

The emerging pharmaceutical markets which probably have absolute spending growth constitute the global pharmerging market.

The rising prevalence of non-transmissible illnesses, aging population, increasing life expectancy, surging government expenditure on health care, and constant research & development are some of the key factors that drive the growth of this market. However, IP protection issues and socio-political issues in cross geography transactions and stringent price control lead to value erosion and restrain the market growth. But growth opportunities in emerging markets and a positive outlook towards the adoption of targeted therapies will fuel the market growth in future.

The global pharmerging market is divided on the basis of product, economy, indications, distribution channel, and region. By product it is divided into pharmaceuticals (branded prescription drugs, generic drugs {branded generics and unbranded generics}, and OTC drugs) and healthcare (medical devices & diagnostic instruments, and others {IT and record management}). On the basis of economic growth levels, the market is segmented into - tier 1, tier 2, and tier 3.

Based on indication the market is segmented into lifestyle diseases, cancers & autoimmune diseases, infectious diseases, and others. On the basis of distribution channel, the market is segmented into hospitals, clinics, retail pharmacies, e-commerce, and drug stores. Geographically the market has been analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, UK, France, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major players profiled in this report include Abbott Laboratories, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, GlaxoSmithKline plc., LUPIN, Tata Consultancy Services Limited, and Sun Pharmaceutical Industries Ltd.

Key Benefits

  • The study provides an in-depth analysis of the market with current trends and future estimations to elucidate imminent investment pockets.
  • It offers a quantitative analysis which is expected to enable stakeholders to capitalize on prevailing market opportunities.
  • Exhaustive analysis of the global pharmerging market by type helps understand the types of pharmerging companies that are currently being used along with the variants that would gain prominence in future.
  • Comprehensive analysis of all geographical regions has been provided, which helps determine prevailing opportunities.
  • Key players have been profiled and their strategies thoroughly analyzed, which helps understand the competitive outlook of the global market.

Pharmerging Market Report Highlights

Aspects Details
By Product Type
  • Pharmaceuticals
    • Branded Prescription Drugs
    • Generic Drugs
      • Branded Generics
      • Unbranded Generics
    • OTC Drugs
  • Healthcare
    • Medical Devices
    • Diagnostic Instruments
    • Others (IT and record management)
By Economy
  • Tier-1
  • Tier-2
  • Tier-3
By Indications
  • Lifestyle Diseases
  • Cancer and autoimmune diseases
  • Infectious Diseases
  • Others
By Distribution Channel
  • Hospitals
  • Clinics
  • Retail Pharmacies
  • E-commerce
  • Drug stores
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players Novartis AG, Merck & Co., Inc., GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Tata Consultancy Services Limited, Koninklijke Philips N.V., Abbott Laboratories, AstraZeneca plc, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Lupin Industries
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: PHARMERGING MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Pharmaceuticals

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. Branded Prescription Drugs

        • 4.2.4.1. Market Size and Forecast
      • 4.2.4. Generic Drugs

        • 4.2.4.1. Market Size and Forecast
        • 4.2.4.2. Branded Generics

          • 4.2.4.2.1. Market Size and Forecast
        • 4.2.4.2. Unbranded Generics

          • 4.2.4.2.1. Market Size and Forecast
      • 4.2.4. OTC Drugs

        • 4.2.4.1. Market Size and Forecast
    • 4.3. Healthcare

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

      • 4.3.4. Medical Devices

        • 4.3.4.1. Market Size and Forecast
      • 4.3.4. Diagnostic Instruments

        • 4.3.4.1. Market Size and Forecast
      • 4.3.4. Others (IT and record management)

        • 4.3.4.1. Market Size and Forecast
  • CHAPTER 5: PHARMERGING MARKET, BY ECONOMY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Economy

    • 5.2. Tier-1

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Tier-2

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Tier-3

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: PHARMERGING MARKET, BY INDICATIONS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Indications

    • 6.2. Lifestyle Diseases

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Cancer And Autoimmune Diseases

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Infectious Diseases

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: PHARMERGING MARKET, BY DISTRIBUTION CHANNEL

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Distribution Channel

    • 7.2. Hospitals

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Clinics

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Retail Pharmacies

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. E-commerce

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

    • 7.6. Drug Stores

      • 7.6.1. Key Market Trends, Growth Factors and Opportunities

      • 7.6.2. Market Size and Forecast, By Region

      • 7.6.3. Market Share Analysis, By Country

  • CHAPTER 8: PHARMERGING MARKET, BY REGION

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By Region

    • 8.2. North America

      • 8.2.1. Key Market Trends and Opportunities

      • 8.2.2. Market Size and Forecast, By Product Type

      • 8.2.3. Market Size and Forecast, By Economy

      • 8.2.4. Market Size and Forecast, By Indications

      • 8.2.5. Market Size and Forecast, By Distribution Channel

      • 8.2.6. Market Size and Forecast, By Country

      • 8.2.7. U.S. Pharmerging Market

        • 8.2.7.1. Market Size and Forecast, By Product Type
        • 8.2.7.2. Market Size and Forecast, By Economy
        • 8.2.7.3. Market Size and Forecast, By Indications
        • 8.2.7.4. Market Size and Forecast, By Distribution Channel
      • 8.2.8. Canada Pharmerging Market

        • 8.2.8.1. Market Size and Forecast, By Product Type
        • 8.2.8.2. Market Size and Forecast, By Economy
        • 8.2.8.3. Market Size and Forecast, By Indications
        • 8.2.8.4. Market Size and Forecast, By Distribution Channel
      • 8.2.9. Mexico Pharmerging Market

        • 8.2.9.1. Market Size and Forecast, By Product Type
        • 8.2.9.2. Market Size and Forecast, By Economy
        • 8.2.9.3. Market Size and Forecast, By Indications
        • 8.2.9.4. Market Size and Forecast, By Distribution Channel
    • 8.3. Europe

      • 8.3.1. Key Market Trends and Opportunities

      • 8.3.2. Market Size and Forecast, By Product Type

      • 8.3.3. Market Size and Forecast, By Economy

      • 8.3.4. Market Size and Forecast, By Indications

      • 8.3.5. Market Size and Forecast, By Distribution Channel

      • 8.3.6. Market Size and Forecast, By Country

      • 8.3.7. France Pharmerging Market

        • 8.3.7.1. Market Size and Forecast, By Product Type
        • 8.3.7.2. Market Size and Forecast, By Economy
        • 8.3.7.3. Market Size and Forecast, By Indications
        • 8.3.7.4. Market Size and Forecast, By Distribution Channel
      • 8.3.8. Germany Pharmerging Market

        • 8.3.8.1. Market Size and Forecast, By Product Type
        • 8.3.8.2. Market Size and Forecast, By Economy
        • 8.3.8.3. Market Size and Forecast, By Indications
        • 8.3.8.4. Market Size and Forecast, By Distribution Channel
      • 8.3.9. Italy Pharmerging Market

        • 8.3.9.1. Market Size and Forecast, By Product Type
        • 8.3.9.2. Market Size and Forecast, By Economy
        • 8.3.9.3. Market Size and Forecast, By Indications
        • 8.3.9.4. Market Size and Forecast, By Distribution Channel
      • 8.3.10. Spain Pharmerging Market

        • 8.3.10.1. Market Size and Forecast, By Product Type
        • 8.3.10.2. Market Size and Forecast, By Economy
        • 8.3.10.3. Market Size and Forecast, By Indications
        • 8.3.10.4. Market Size and Forecast, By Distribution Channel
      • 8.3.11. UK Pharmerging Market

        • 8.3.11.1. Market Size and Forecast, By Product Type
        • 8.3.11.2. Market Size and Forecast, By Economy
        • 8.3.11.3. Market Size and Forecast, By Indications
        • 8.3.11.4. Market Size and Forecast, By Distribution Channel
      • 8.3.12. Russia Pharmerging Market

        • 8.3.12.1. Market Size and Forecast, By Product Type
        • 8.3.12.2. Market Size and Forecast, By Economy
        • 8.3.12.3. Market Size and Forecast, By Indications
        • 8.3.12.4. Market Size and Forecast, By Distribution Channel
      • 8.3.13. Rest Of Europe Pharmerging Market

        • 8.3.13.1. Market Size and Forecast, By Product Type
        • 8.3.13.2. Market Size and Forecast, By Economy
        • 8.3.13.3. Market Size and Forecast, By Indications
        • 8.3.13.4. Market Size and Forecast, By Distribution Channel
    • 8.4. Asia-Pacific

      • 8.4.1. Key Market Trends and Opportunities

      • 8.4.2. Market Size and Forecast, By Product Type

      • 8.4.3. Market Size and Forecast, By Economy

      • 8.4.4. Market Size and Forecast, By Indications

      • 8.4.5. Market Size and Forecast, By Distribution Channel

      • 8.4.6. Market Size and Forecast, By Country

      • 8.4.7. China Pharmerging Market

        • 8.4.7.1. Market Size and Forecast, By Product Type
        • 8.4.7.2. Market Size and Forecast, By Economy
        • 8.4.7.3. Market Size and Forecast, By Indications
        • 8.4.7.4. Market Size and Forecast, By Distribution Channel
      • 8.4.8. Japan Pharmerging Market

        • 8.4.8.1. Market Size and Forecast, By Product Type
        • 8.4.8.2. Market Size and Forecast, By Economy
        • 8.4.8.3. Market Size and Forecast, By Indications
        • 8.4.8.4. Market Size and Forecast, By Distribution Channel
      • 8.4.9. India Pharmerging Market

        • 8.4.9.1. Market Size and Forecast, By Product Type
        • 8.4.9.2. Market Size and Forecast, By Economy
        • 8.4.9.3. Market Size and Forecast, By Indications
        • 8.4.9.4. Market Size and Forecast, By Distribution Channel
      • 8.4.10. South Korea Pharmerging Market

        • 8.4.10.1. Market Size and Forecast, By Product Type
        • 8.4.10.2. Market Size and Forecast, By Economy
        • 8.4.10.3. Market Size and Forecast, By Indications
        • 8.4.10.4. Market Size and Forecast, By Distribution Channel
      • 8.4.11. Australia Pharmerging Market

        • 8.4.11.1. Market Size and Forecast, By Product Type
        • 8.4.11.2. Market Size and Forecast, By Economy
        • 8.4.11.3. Market Size and Forecast, By Indications
        • 8.4.11.4. Market Size and Forecast, By Distribution Channel
      • 8.4.12. Thailand Pharmerging Market

        • 8.4.12.1. Market Size and Forecast, By Product Type
        • 8.4.12.2. Market Size and Forecast, By Economy
        • 8.4.12.3. Market Size and Forecast, By Indications
        • 8.4.12.4. Market Size and Forecast, By Distribution Channel
      • 8.4.13. Malaysia Pharmerging Market

        • 8.4.13.1. Market Size and Forecast, By Product Type
        • 8.4.13.2. Market Size and Forecast, By Economy
        • 8.4.13.3. Market Size and Forecast, By Indications
        • 8.4.13.4. Market Size and Forecast, By Distribution Channel
      • 8.4.14. Indonesia Pharmerging Market

        • 8.4.14.1. Market Size and Forecast, By Product Type
        • 8.4.14.2. Market Size and Forecast, By Economy
        • 8.4.14.3. Market Size and Forecast, By Indications
        • 8.4.14.4. Market Size and Forecast, By Distribution Channel
      • 8.4.15. Rest of Asia Pacific Pharmerging Market

        • 8.4.15.1. Market Size and Forecast, By Product Type
        • 8.4.15.2. Market Size and Forecast, By Economy
        • 8.4.15.3. Market Size and Forecast, By Indications
        • 8.4.15.4. Market Size and Forecast, By Distribution Channel
    • 8.5. LAMEA

      • 8.5.1. Key Market Trends and Opportunities

      • 8.5.2. Market Size and Forecast, By Product Type

      • 8.5.3. Market Size and Forecast, By Economy

      • 8.5.4. Market Size and Forecast, By Indications

      • 8.5.5. Market Size and Forecast, By Distribution Channel

      • 8.5.6. Market Size and Forecast, By Country

      • 8.5.7. Brazil Pharmerging Market

        • 8.5.7.1. Market Size and Forecast, By Product Type
        • 8.5.7.2. Market Size and Forecast, By Economy
        • 8.5.7.3. Market Size and Forecast, By Indications
        • 8.5.7.4. Market Size and Forecast, By Distribution Channel
      • 8.5.8. South Africa Pharmerging Market

        • 8.5.8.1. Market Size and Forecast, By Product Type
        • 8.5.8.2. Market Size and Forecast, By Economy
        • 8.5.8.3. Market Size and Forecast, By Indications
        • 8.5.8.4. Market Size and Forecast, By Distribution Channel
      • 8.5.9. Saudi Arabia Pharmerging Market

        • 8.5.9.1. Market Size and Forecast, By Product Type
        • 8.5.9.2. Market Size and Forecast, By Economy
        • 8.5.9.3. Market Size and Forecast, By Indications
        • 8.5.9.4. Market Size and Forecast, By Distribution Channel
      • 8.5.10. UAE Pharmerging Market

        • 8.5.10.1. Market Size and Forecast, By Product Type
        • 8.5.10.2. Market Size and Forecast, By Economy
        • 8.5.10.3. Market Size and Forecast, By Indications
        • 8.5.10.4. Market Size and Forecast, By Distribution Channel
      • 8.5.11. Argentina Pharmerging Market

        • 8.5.11.1. Market Size and Forecast, By Product Type
        • 8.5.11.2. Market Size and Forecast, By Economy
        • 8.5.11.3. Market Size and Forecast, By Indications
        • 8.5.11.4. Market Size and Forecast, By Distribution Channel
      • 8.5.12. Rest of LAMEA Pharmerging Market

        • 8.5.12.1. Market Size and Forecast, By Product Type
        • 8.5.12.2. Market Size and Forecast, By Economy
        • 8.5.12.3. Market Size and Forecast, By Indications
        • 8.5.12.4. Market Size and Forecast, By Distribution Channel
  • CHAPTER 9: COMPETITIVE LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top Winning Strategies

    • 9.3. Product Mapping Of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Top Player Positioning,2022

  • CHAPTER 10: COMPANY PROFILES

    • 10.1. Abbott Laboratories

      • 10.1.1. Company Overview

      • 10.1.2. Key Executives

      • 10.1.3. Company Snapshot

      • 10.1.4. Operating Business Segments

      • 10.1.5. Product Portfolio

      • 10.1.6. Business Performance

      • 10.1.7. Key Strategic Moves and Developments

    • 10.2. Koninklijke Philips N.V.

      • 10.2.1. Company Overview

      • 10.2.2. Key Executives

      • 10.2.3. Company Snapshot

      • 10.2.4. Operating Business Segments

      • 10.2.5. Product Portfolio

      • 10.2.6. Business Performance

      • 10.2.7. Key Strategic Moves and Developments

    • 10.3. F. Hoffmann-La Roche Ltd.

      • 10.3.1. Company Overview

      • 10.3.2. Key Executives

      • 10.3.3. Company Snapshot

      • 10.3.4. Operating Business Segments

      • 10.3.5. Product Portfolio

      • 10.3.6. Business Performance

      • 10.3.7. Key Strategic Moves and Developments

    • 10.4. Merck And Co., Inc.

      • 10.4.1. Company Overview

      • 10.4.2. Key Executives

      • 10.4.3. Company Snapshot

      • 10.4.4. Operating Business Segments

      • 10.4.5. Product Portfolio

      • 10.4.6. Business Performance

      • 10.4.7. Key Strategic Moves and Developments

    • 10.5. Novartis AG

      • 10.5.1. Company Overview

      • 10.5.2. Key Executives

      • 10.5.3. Company Snapshot

      • 10.5.4. Operating Business Segments

      • 10.5.5. Product Portfolio

      • 10.5.6. Business Performance

      • 10.5.7. Key Strategic Moves and Developments

    • 10.6. Johnson And Johnson

      • 10.6.1. Company Overview

      • 10.6.2. Key Executives

      • 10.6.3. Company Snapshot

      • 10.6.4. Operating Business Segments

      • 10.6.5. Product Portfolio

      • 10.6.6. Business Performance

      • 10.6.7. Key Strategic Moves and Developments

    • 10.7. Teva Pharmaceutical Industries Ltd.

      • 10.7.1. Company Overview

      • 10.7.2. Key Executives

      • 10.7.3. Company Snapshot

      • 10.7.4. Operating Business Segments

      • 10.7.5. Product Portfolio

      • 10.7.6. Business Performance

      • 10.7.7. Key Strategic Moves and Developments

    • 10.8. AstraZeneca Plc

      • 10.8.1. Company Overview

      • 10.8.2. Key Executives

      • 10.8.3. Company Snapshot

      • 10.8.4. Operating Business Segments

      • 10.8.5. Product Portfolio

      • 10.8.6. Business Performance

      • 10.8.7. Key Strategic Moves and Developments

    • 10.9. GlaxoSmithKline Plc.

      • 10.9.1. Company Overview

      • 10.9.2. Key Executives

      • 10.9.3. Company Snapshot

      • 10.9.4. Operating Business Segments

      • 10.9.5. Product Portfolio

      • 10.9.6. Business Performance

      • 10.9.7. Key Strategic Moves and Developments

    • 10.10. Lupin Industries

      • 10.10.1. Company Overview

      • 10.10.2. Key Executives

      • 10.10.3. Company Snapshot

      • 10.10.4. Operating Business Segments

      • 10.10.5. Product Portfolio

      • 10.10.6. Business Performance

      • 10.10.7. Key Strategic Moves and Developments

    • 10.11. Tata Consultancy Services Limited

      • 10.11.1. Company Overview

      • 10.11.2. Key Executives

      • 10.11.3. Company Snapshot

      • 10.11.4. Operating Business Segments

      • 10.11.5. Product Portfolio

      • 10.11.6. Business Performance

      • 10.11.7. Key Strategic Moves and Developments

    • 10.12. Sun Pharmaceutical Industries Ltd.

      • 10.12.1. Company Overview

      • 10.12.2. Key Executives

      • 10.12.3. Company Snapshot

      • 10.12.4. Operating Business Segments

      • 10.12.5. Product Portfolio

      • 10.12.6. Business Performance

      • 10.12.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL PHARMERGING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL PHARMERGING MARKET FOR PHARMACEUTICALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL PHARMERGING MARKET FOR HEALTHCARE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL PHARMERGING MARKET, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL PHARMERGING MARKET FOR TIER-1, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL PHARMERGING MARKET FOR TIER-2, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL PHARMERGING MARKET FOR TIER-3, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL PHARMERGING MARKET, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL PHARMERGING MARKET FOR LIFESTYLE DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL PHARMERGING MARKET FOR CANCER AND AUTOIMMUNE DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL PHARMERGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL PHARMERGING MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL PHARMERGING MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL PHARMERGING MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL PHARMERGING MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL PHARMERGING MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL PHARMERGING MARKET FOR E-COMMERCE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL PHARMERGING MARKET FOR DRUG STORES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL PHARMERGING MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA PHARMERGING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 25. U.S. PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 27. U.S. PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 28. U.S. PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. CANADA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. CANADA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 31. CANADA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 32. CANADA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. MEXICO PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 35. MEXICO PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 36. MEXICO PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE PHARMERGING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 38. EUROPE PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. EUROPE PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 40. EUROPE PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 41. EUROPE PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. FRANCE PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. FRANCE PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 44. FRANCE PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 45. FRANCE PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. GERMANY PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. GERMANY PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 48. GERMANY PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 49. GERMANY PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. ITALY PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. ITALY PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 52. ITALY PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 53. ITALY PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 54. SPAIN PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 55. SPAIN PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 56. SPAIN PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 57. SPAIN PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. UK PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. UK PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 60. UK PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 61. UK PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. RUSSIA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. RUSSIA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 64. RUSSIA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 65. RUSSIA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. REST OF EUROPE PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 67. REST OF EUROPE PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 68. REST OF EUROPE PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF EUROPE PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. ASIA-PACIFIC PHARMERGING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 71. ASIA-PACIFIC PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. ASIA-PACIFIC PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 73. ASIA-PACIFIC PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 74. ASIA-PACIFIC PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. CHINA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. CHINA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 77. CHINA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 78. CHINA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 79. JAPAN PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 80. JAPAN PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 81. JAPAN PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 82. JAPAN PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. INDIA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. INDIA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 85. INDIA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 86. INDIA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. SOUTH KOREA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. SOUTH KOREA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 89. SOUTH KOREA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 90. SOUTH KOREA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 91. AUSTRALIA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. AUSTRALIA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 93. AUSTRALIA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 94. AUSTRALIA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 95. THAILAND PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 96. THAILAND PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 97. THAILAND PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 98. THAILAND PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 99. MALAYSIA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 100. MALAYSIA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 101. MALAYSIA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 102. MALAYSIA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. INDONESIA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 104. INDONESIA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 105. INDONESIA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 106. INDONESIA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 107. REST OF ASIA PACIFIC PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 108. REST OF ASIA PACIFIC PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 109. REST OF ASIA PACIFIC PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 110. REST OF ASIA PACIFIC PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 111. LAMEA PHARMERGING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 112. LAMEA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 113. LAMEA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 114. LAMEA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 115. LAMEA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 116. BRAZIL PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 117. BRAZIL PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 118. BRAZIL PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 119. BRAZIL PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 120. SOUTH AFRICA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 121. SOUTH AFRICA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 122. SOUTH AFRICA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 123. SOUTH AFRICA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 124. SAUDI ARABIA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 125. SAUDI ARABIA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 126. SAUDI ARABIA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 127. SAUDI ARABIA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 128. UAE PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 129. UAE PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 130. UAE PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 131. UAE PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 132. ARGENTINA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 133. ARGENTINA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 134. ARGENTINA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 135. ARGENTINA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 136. REST OF LAMEA PHARMERGING, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 137. REST OF LAMEA PHARMERGING, BY ECONOMY, 2022-2032 ($MILLION)
  • TABLE 138. REST OF LAMEA PHARMERGING, BY INDICATIONS, 2022-2032 ($MILLION)
  • TABLE 139. REST OF LAMEA PHARMERGING, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 140. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 141. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 142. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 143. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 144. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 146. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 147. KONINKLIJKE PHILIPS N.V.: OPERATING SEGMENTS
  • TABLE 148. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 149. KONINKLIJKE PHILIPS N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 151. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 152. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 153. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 154. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 156. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 157. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 158. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 159. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 160. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 161. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 162. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 163. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 164. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 165. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 166. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 167. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 168. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 169. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 170. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 171. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 172. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 173. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 174. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 175. ASTRAZENECA PLC: KEY EXECUTIVES
  • TABLE 176. ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 177. ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 178. ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 179. ASTRAZENECA PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 180. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 181. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 182. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 183. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 184. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 185. LUPIN INDUSTRIES: KEY EXECUTIVES
  • TABLE 186. LUPIN INDUSTRIES: COMPANY SNAPSHOT
  • TABLE 187. LUPIN INDUSTRIES: OPERATING SEGMENTS
  • TABLE 188. LUPIN INDUSTRIES: PRODUCT PORTFOLIO
  • TABLE 189. LUPIN INDUSTRIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 190. TATA CONSULTANCY SERVICES LIMITED: KEY EXECUTIVES
  • TABLE 191. TATA CONSULTANCY SERVICES LIMITED: COMPANY SNAPSHOT
  • TABLE 192. TATA CONSULTANCY SERVICES LIMITED: OPERATING SEGMENTS
  • TABLE 193. TATA CONSULTANCY SERVICES LIMITED: PRODUCT PORTFOLIO
  • TABLE 194. TATA CONSULTANCY SERVICES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 195. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 196. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 197. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 198. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 199. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMERGING MARKET SEGMENTATION
  • FIGURE 2. GLOBAL PHARMERGING MARKET
  • FIGURE 3. SEGMENTATION PHARMERGING MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN PHARMERGING MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALPHARMERGING MARKET
  • FIGURE 11. PHARMERGING MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. PHARMERGING MARKET FOR PHARMACEUTICALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. PHARMERGING MARKET FOR HEALTHCARE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. PHARMERGING MARKET SEGMENTATION, BY BY ECONOMY
  • FIGURE 15. PHARMERGING MARKET FOR TIER-1, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. PHARMERGING MARKET FOR TIER-2, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. PHARMERGING MARKET FOR TIER-3, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. PHARMERGING MARKET SEGMENTATION, BY BY INDICATIONS
  • FIGURE 19. PHARMERGING MARKET FOR LIFESTYLE DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. PHARMERGING MARKET FOR CANCER AND AUTOIMMUNE DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. PHARMERGING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. PHARMERGING MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. PHARMERGING MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNEL
  • FIGURE 24. PHARMERGING MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. PHARMERGING MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. PHARMERGING MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. PHARMERGING MARKET FOR E-COMMERCE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. PHARMERGING MARKET FOR DRUG STORES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 32. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 33. COMPETITIVE DASHBOARD
  • FIGURE 34. COMPETITIVE HEATMAP: PHARMERGING MARKET
  • FIGURE 35. Top player positioning, 2022
  • FIGURE 36. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. KONINKLIJKE PHILIPS N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. KONINKLIJKE PHILIPS N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. ASTRAZENECA PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. ASTRAZENECA PLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. ASTRAZENECA PLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. LUPIN INDUSTRIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. LUPIN INDUSTRIES: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. LUPIN INDUSTRIES: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 66. TATA CONSULTANCY SERVICES LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 67. TATA CONSULTANCY SERVICES LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 68. TATA CONSULTANCY SERVICES LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 71. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Pharmerging Market

Start reading.
This Report and over 67,071+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers